TYK2 and lung cancer: Using an established partial loss‐of‐function variant to mimic therapeutic TYK2 inhibition, we show that potential protection from autoimmunity mediated by TYK2 inhibition may be counteracted by an increased risk of lung cancer and non‐Hodgkin lymphoma.